Diabetic Foot Ulcers Pipeline Insight

DelveInsight’s, “Diabetic Foot Ulcers Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Diabetic Foot Ulcers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Diabetic Foot Ulcer Understanding

Diabetic Foot Ulcers Overview

Diabetic foot ulcers (DFUs) are chronic, non-healing wounds that occur on the feet of individuals with diabetes, primarily resulting from a combination of peripheral neuropathy, poor blood circulation (peripheral arterial disease), and impaired wound healing. These ulcers are a serious complication of diabetes, often leading to infection, tissue damage, and in severe cases, lower-limb amputation, while also reflecting underlying systemic vascular disease and increased mortality risk. 

Diabetic foot ulcers typically present as open sores or wounds, most commonly on pressure areas of the foot such as the sole, heel, or toes. Early signs may include redness, swelling, or callus formation, often without pain due to nerve damage (neuropathy). As the condition progresses, patients may notice drainage, foul odor, or visible tissue breakdown, sometimes accompanied by infection signs such as warmth, pus, or fever. In more advanced stages, ulcers may deepen, exposing underlying structures (e.g., muscle or bone), and can lead to blackened tissue (necrosis) or gangrene if blood supply is severely compromised. 

Diabetic foot ulcers (DFUs) arise from a multifactorial interplay of peripheral neuropathy, peripheral arterial disease (PAD), abnormal biomechanics, impaired wound healing, and infection. Chronic hyperglycemia leads to nerve damage, resulting in loss of protective sensation, dry skin, and muscle atrophy, which in turn causes foot deformities and increased plantar pressure. These mechanical stresses, combined with callus formation, make the skin highly vulnerable to breakdown and ulceration. Concurrently, PAD reduces blood flow and oxygen delivery, accelerating tissue damage and limiting healing capacity. At the cellular level, impaired wound healing is driven by chronic inflammation, reduced angiogenesis, fibroblast dysfunction, and accumulation of advanced glycation end products, all of which delay tissue repair. 

Diabetic foot ulcers (DFUs) develop from a combination of underlying causes, primarily categorized into neuropathic, ischemic, and neuro-ischemic ulcers. Neuropathic ulcers arise due to peripheral neuropathy, where loss of sensation and abnormal foot biomechanics lead to unnoticed trauma and pressure-induced skin breakdown, typically on weight-bearing areas. Ischemic ulcers result from peripheral arterial disease (PAD), where reduced blood flow causes tissue ischemia, commonly affecting the toes or foot margins and often presenting as painful lesions. Neuro-ischemic ulcers occur when both neuropathy and PAD coexist, leading to more complex and severe ulceration, especially in patients with long-standing diabetes. 

The diagnosis of diabetic foot ulcers (DFUs) involves a comprehensive clinical, laboratory, and imaging-based evaluation. Laboratory tests such as complete blood count, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and procalcitonin help assess infection and inflammation, while HbA1c is used to evaluate glycemic control. 
Microbiological diagnosis relies on deep tissue or biopsy cultures, with superficial swabs discouraged. Imaging plays a key role, with plain X-rays used to detect bone involvement or deformities, and MRI providing detailed assessment of osteomyelitis and deep tissue infection when needed. Evaluation of peripheral arterial disease (PAD) using tools such as ankle-brachial index (ABI), toe pressures, and Doppler studies is essential to assess blood flow and predict healing potential. 

Management of DFUs requires a multidisciplinary, evidence-based approach focused on wound healing and complication prevention. Offloading (pressure relief) is central, especially using devices like total contact casts for neuropathic ulcers. Regular debridement of necrotic tissue and appropriate wound dressings support healing. Antibiotics are used only when infection is present, with therapy tailored to severity and microbial profile. In cases of osteomyelitis, prolonged antibiotics or surgical intervention (including minor amputation) may be necessary.

"Diabetic Foot Ulcers Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Foot Ulcers pipeline landscape is provided which includes the disease overview and Diabetic Foot Ulcers treatment guidelines. The assessment part of the report embraces, in depth Diabetic Foot Ulcers commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Foot Ulcers collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Diabetic Foot Ulcers Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Foot Ulcers R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Foot Ulcers.

Diabetic Foot Ulcers Emerging Drugs Analysis

This segment of the Diabetic Foot Ulcers report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic Foot Ulcers Emerging Drugs

SkinTE: Polarity Bio

SkinTE is an investigational autologous multicellular skin therapy designed to leverage the body’s innate capacity to regenerate functional skin. By utilizing the full cellular and extracellular matrix composition of native skin, SkinTE is designed to provide the essential biological components needed to initiate, stabilize, and support the wound healing process in chronic wounds such as diabetic foot ulcers. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Diabetic Foot Ulcers.

AUP-16: Aurealis Therapeutics

AUP-16 is a novel, topically applied "4-in-1" cell and gene therapy developed by Aurealis Therapeutics for treating chronic wounds, such as diabetic foot ulcers (DFUs). It uses genetically engineered Lactococcus cremoris bacteria to produce human growth factors and cytokines (FGF-2, IL-4, CSF-1) directly in the wound to promote tissue regeneration. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Diabetic Foot Ulcers.

CYP-006TK: Cynata Therapeutics Limited

CYP-006TK is Cynata's Cymerus™ iPSC-derived MSC topical wound dressing product candidate, which comprises MSCs seeded onto a novel silicone dressing. This innovative approach allows for direct application of MSCs to the wound site, potentially enhancing healing and reducing complications. Cynata has acquired the dressing technology from leading manufacturer of innovative biomedical coatings, TekCyte Limited. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Diabetic Foot Ulcers.

Further product details are provided in the report……..

Diabetic Foot Ulcers Drug Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Foot Ulcers drugs segregated based on following parameters that define the scope of the report, such as:

Major Diabetic Foot Ulcers Players in Diabetic Foot Ulcers

There are approx. 20+ key companies which are developing the therapies for Diabetic Foot Ulcers. The companies which have their Diabetic Foot Ulcers drug candidates in the most advanced stage, i.e. Phase III include, Polarity Bio.

Diabetic Foot Ulcers Clinical Trial Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Diabetic Foot Ulcers Drug Route of Administration

Diabetic Foot Ulcers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Diabetic Foot Ulcers Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Diabetic Foot Ulcers Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Foot Ulcers Clinical Trial Activities 

The Diabetic Foot Ulcers Pipeline report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Foot Ulcers therapeutic drugs key players involved in developing key drugs.

Diabetic Foot Ulcers Pipeline Development Activities

The Diabetic Foot Ulcers Clinical Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Foot Ulcers drugs.

Diabetic Foot Ulcers Pipeline Report Insights

• Diabetic Foot Ulcers Pipeline Analysis
• Diabetic Foot Ulcers Therapeutic Assessment
• Diabetic Foot Ulcers Unmet Needs
• Impact of Diabetic Foot Ulcers Drugs

Diabetic Foot Ulcers Pipeline Report Assessment

• Diabetic Foot Ulcers Pipeline Product Profiles
• Diabetic Foot Ulcers Therapeutic Assessment
• Diabetic Foot Ulcers Pipeline Assessment
• Diabetic Foot Ulcers Inactive drugs assessment
• Diabetic Foot Ulcers Market Unmet Needs

Key Questions Answered in the Diabetic Foot Ulcers Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Diabetic Foot Ulcers drugs?
• How many Diabetic Foot Ulcers drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Foot Ulcers?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic Foot Ulcers therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Diabetic Foot Ulcers and their status?
• What are the key designations that have been granted to the emerging drugs?

Diabetic Foot Ulcers Key Players

• Polarity Bio
• Aurealis Therapeutics
• Cynata Therapeutics Limited
• Blue Blood Biotech Corp.
• Eluciderm Inc
• Recce Pharmaceuticals
• Lakewood Amedex Biotherapeutics Inc.
• FibroBiologics
• NOxy Health Products, LLC
• Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.

Diabetic Foot Ulcers Key Products

• SkinTE
• AUP-16
• CYP-006TK
• BB-101
• ELU42
• RECCE® 327
• Nu-3
• CYWC-628
• NOX-1416
• MDI-1228